The China Flu Diagnostic and Treatment market is forecast to grow at a CAGR of 22.0%, reaching USD 23.8 billion in 2031 from USD 8.8 billion in 2026.
Highlights:
- 1Regulatory EnforcementNew NMPA "two-step release" protocols are currently mandating that Marketing Authorization Holders (MAHs) perform independent marketing release, preventing delegation to contract manufacturers.
- 2High-Severity DemandThe 2024–2025 flu season reached high-severity status across all age groups, currently driving a surge in medical visits to 23 million for respiratory-related illnesses.
- 3Molecular DisplacementSales for molecular solutions at Roche Diagnostics grew in 2025, currently offsetting the impact of local healthcare pricing reforms in China.
- 4Strategic ConsolidationAbbott is currently finalizing its acquisition of Exact Sciences in Q2 2026 to raise its total diagnostic sales to over USD 12 billion annually.
The Chinese flu diagnostic and treatment market is currently undergoing a regulatory maturation phase as the National Medical Products Administration (NMPA) implements stricter Quality Management System (QMS) legislation effective November 1, 2026. Healthcare providers are responding to this shift by upgrading laboratory infrastructure to meet revised Good Manufacturing Practice (GMP) requirements for medical devices. This transition is becoming critical as China CDC's virologic surveillance continues to identify high-severity seasons, such as the 2024–2025 period which saw 51 million illnesses. Structural demand is increasing for analyzer-based digital readers that provide consistent results compared to human review. Consequently, the industry is reaching an outcome where foreign and domestic manufacturers must demonstrate rigorous verification and validation (V&V) to maintain market access.
Market Dynamics
Drivers
Rising Epidemic Frequency: Increased seasonal and pandemic surveillance is currently propelling the adoption of molecular diagnostic methods across China.
Point-of-Care Expansion: Decentralized clinical use is growing as healthcare facilities are currently enlisting automated, data-linked testing kits to reduce diagnostic errors.
Multiplex Integration: The introduction of tests detecting influenza alongside other respiratory pathogens is currently increasing clinical utility for outpatient clinics.
Technological Convergence: AI and machine learning are currently supporting the automation of test interpretation to enhance sensitivity relative to traditional optical methods.
Restraints and Opportunities
Pricing Reform Pressure: Centralized procurement and healthcare pricing reforms in China are continuing to challenge the profit margins of global diagnostic leaders.
Stricter Compliance Hurdles: The elevation of QMS requirements is currently forcing foreign manufacturers to submit home-country approval and extensive evidence of quality assurance.
Home-Testing Kits (Opportunity): Growing preference for decentralized healthcare is providing a significant opening for the expansion of influenza home-diagnostic kits.
Pathology and Molecular Solutions (Opportunity): Strong demand in these segments is currently providing a pathway for companies to offset losses in traditional diagnostic sectors.
Supply Chain Analysis
The supply chain for flu diagnostics in China is currently shifting toward a model of localized quality control as NMPA's Announcement No. 107 of 2025 elevates management responsibility for all manufacturers. MAHs are increasing their oversight of contract manufacturing organizations (CMOs) to comply with new "marketing release" mandates. This evolution is becoming critical as the demand for rapid molecular assays is currently outpacing the supply of traditional optical lateral flow tests.
Government Regulations
Regulation/Policy | Country/Region | Impact on Market |
NMPA QMS Legislation | China | Takes effect Nov 1, 2026; mandates rigorous GMP and quality risk management throughout the device lifecycle. |
Medical Device GMP (No. 107) | China | Bolsters requirements for validation, verification, and computerized system validation (CSV). |
China Field Epidemiology Program | China | Enhances local capacity for outbreak response and influenza virus detection. |
Key Developments
Abbott-Exact Sciences Merger (March 2026): Abbott is currently integrating Exact Sciences' portfolio to bolster its global diagnostic footprint.
NMPA QMS Final Implementation (November 2025): Regulators confirmed that new legislation for medical device quality management will be mandatory starting November 2026.
Roche Next-Gen Sequencing Launch (October 2025): Roche successfully launched a technology capable of decoding an entire human genome in less than four hours to set new standards in molecular diagnostics.
Market Segmentation
By Offering
Rapid molecular assays are currently gaining market share over conventional RIDTs as they offer superior sensitivity and are essential for timely public health responses. Diagnostics are witnessing a shift toward semi-quantitative and digital-read formats. This transition is resulting in a market where therapeutics are becoming more targeted based on rapid, strain-specific identification.
By End-User
Hospital laboratories remain the primary segment for molecular diagnostics, as they are currently upgrading equipment to comply with NMPA's separate "Quality Assurance" chapters. Outpatient clinics are currently adopting digital RIDTs due to their ease of use and lack of specialized training requirements during busy flu seasons. Consequently, reference laboratories are reaching a structural outcome where they handle complex pandemic surveillance and high-volume seasonal testing.
By Age Group
The 65 years segment is currently accounting for 57% of flu-related hospitalizations and 71% of deaths, driving a critical need for accurate diagnostic monitoring in this group. Children (0-14 years) are witnessing high demand for rapid testing as school-based outbreaks are currently a major driver for pediatric medical visits. This movement is forcing a realignment of the market toward age-specific diagnostic interventions and vaccination effectiveness assessments.
List of Companies
Abbott
Roche Diagnostics China
BD (Becton, Dickinson and Company)
Thermo Fisher Scientific
3M
Quidel Corporation
F. Hoffmann-La Roche Ltd
Hologic, Inc.
Meridian Bioscience, Inc.
SEKISUI Diagnostics, LLC
Company Profiles
Roche Diagnostics China: Strategically distinct for its focus on pathology and molecular solutions, the company is successfully offsetting China's pricing reforms through high-efficiency gains and 7% group sales growth in 2025.
Abbott: Notable for its robust innovation pipeline, the company is currently expanding its diagnostic leadership to over USD 12 billion through strategic global acquisitions and product launches.
Quidel Corporation: Distinguished by its strength in point-of-care testing, the company is currently leveraging the shift toward digital RIDTs and analyzer-based readers for consistent clinical results.
Analyst View
The Chinese flu diagnostic market is entering a "Regulatory Conformity" phase. Success for participants now depends on navigating NMPA's strict 2026 GMP requirements while successfully integrating molecular precision into the burgeoning outpatient and point-of-care segments through 2031.
China Flu Diagnostic and Treatment Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 8.8 billion |
| Total Market Size in 2031 | USD 23.8 billion |
| Forecast Unit | Billion |
| Growth Rate | 22.0% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | TYPE OF FLU, OFFERING, AGE GROUP, END-USER |
| Companies |
|
| Customization Scope | 15% Free Customization included with purchase — Request Custom Breakdown → |
| Sample & Data Access | PDF Sample, Excel Databook & Analyst Briefing — Download Free Sample → |
Market Segmentation
By Type of Flu
- Type A
- Type B
By Offering
- Diagnostics
- Rapid Influenza Diagnostic Test
- Rapid Molecular Assay
- Others
- Therapeutics
By Age Group
- 0–14 Years
- 15–64 Years
- ?65 Years
By End-User
- Hospital Laboratory
- Outpatient Clinic
- Reference Laboratory
Table of Contents
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. CHINA FLU DIAGNOSTIC AND TREATMENT MARKET ANALYSIS, BY TYPE OF FLU
5.1. Introduction
5.2. Type A
5.3. Type B
6. CHINA FLU DIAGNOSTIC AND TREATMENT MARKET ANALYSIS, BY OFFERING
6.1. Introduction
6.2. Diagnostics
6.2.1. Rapid Influenza Diagnostic Test
6.2.2. Rapid Molecular Assay
6.2.3. Others
6.3. Therapeutics
7. CHINA FLU DIAGNOSTIC AND TREATMENT MARKET ANALYSIS, BY AGE GROUP
7.1. Introduction
7.2. 0-14 Years
7.3. 15-64 Years
7.4. >=65 Years
8. CHINA FLU DIAGNOSTIC AND TREATMENT MARKET ANALYSIS, BY END-USER
8.1. Introduction
8.2. Hospital Laboratory
8.3. Outpatient Clinic
8.4. Reference Laboratory
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Abbott
10.2. Roche Diagnostics China
10.3. BD
10.4. Thermo Fisher Scientific
10.5. 3M
10.6. Quidel Corporation
10.7. F. Hoffmann-La Roche Ltd
10.8. Hologic, Inc.
10.9. Meridian Bioscience, Inc.
10.10. SEKISUI Diagnostics, LLC
List of Figures
List of Companies
Frequently asked questions
What is the projected market size and growth rate for the China Flu Diagnostic and Treatment market from 2026 to 2031?
The China Flu Diagnostic and Treatment market is forecast to grow at a robust Compound Annual Growth Rate (CAGR) of 22.0%. This growth trajectory will see the market expand significantly from USD 8.8 billion in 2026 to an estimated USD 23.8 billion by 2031, driven by increasing diagnostic and treatment demand from high-severity flu seasons.
How will new NMPA regulations impact manufacturers in China's flu diagnostic and treatment sector post-2026?
Effective November 1, 2026, the NMPA's stricter Quality Management System (QMS) legislation and revised Good Manufacturing Practice (GMP) requirements will significantly impact manufacturers. Marketing Authorization Holders (MAHs) must implement independent marketing release, and both foreign and domestic manufacturers will need to demonstrate rigorous verification and validation (V&V) to maintain market access, with foreign entities facing elevated compliance hurdles requiring home-country approval.
What are the primary drivers propelling the growth of the China Flu Diagnostic and Treatment market?
Key drivers include the rising epidemic frequency, with 51 million illnesses in the 2024–2025 season, which propels the adoption of molecular diagnostic methods. Additionally, point-of-care expansion with automated, data-linked testing kits, multiplex integration detecting multiple respiratory pathogens, and technological convergence through AI/machine learning for enhanced test interpretation are all contributing to market growth.
Which major companies are making significant strategic moves in the China Flu Diagnostic and Treatment market?
Roche Diagnostics demonstrated strategic strength with growth in its molecular solutions sales in 2025, effectively offsetting local healthcare pricing reforms. Abbott is also making a significant move by finalizing its acquisition of Exact Sciences in Q2 2026, a strategic consolidation aimed at raising its total diagnostic sales to over USD 12 billion annually, signaling increased competitive activity.
What are the main restraints and challenges within the China Flu Diagnostic and Treatment market?
The China Flu Diagnostic and Treatment Market faces considerable challenges from centralized procurement and healthcare pricing reforms, which continue to pressure the profit margins of global diagnostic leaders. Furthermore, the elevation of NMPA QMS requirements presents stricter compliance hurdles, necessitating extensive evidence of quality assurance and, for foreign manufacturers, home-country approval.
What key opportunities are emerging in the China Flu Diagnostic and Treatment market?
A significant opportunity is emerging in home-testing kits due to a growing preference for decentralized healthcare. There is also increasing structural demand for analyzer-based digital readers, which provide more consistent results compared to human review, driving innovation in diagnostic technologies. Multiplex integration also presents an opportunity by increasing the clinical utility of tests for outpatient clinics.
Cite this report
Knowledge Sourcing Intelligence. (May 2026). China Flu Diagnostic and Treatment Market - Strategic Insights and Forecasts (2026-2031). https://www.knowledge-sourcing.com/report/china-flu-diagnostic-and-treatment-market